Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice  by Wouters, Kristiaan et al.
FEBS Letters 584 (2010) 1001–1005journal homepage: www.FEBSLetters .orgIntrahepatic cholesterol inﬂuences progression, inhibition and reversal
of non-alcoholic steatohepatitis in hyperlipidemic mice
Kristiaan Wouters a,*, Marc van Bilsen a, Patrick J. van Gorp a, Veerle Bieghs a, Dieter Lütjohann b,
Anja Kerksiek b, Bart Staels c,d,e,f, Marten H. Hofker g, Ronit Shiri-Sverdlov a
aDepts. of Molecular Genetics, Pathology and Physiology, Nutrition and Toxicology Research (NUTRIM) and Cardiovascular Research (CARIM)
Institutes of Maastricht University Maastricht, Maastricht, The Netherlands
b Institute of Clinical Chemistry and Pharmacology, D-53105 Bonn, University of Bonn, Bonn, Germany
cUniv. Lille Nord de France, F-59000, Lille, France
d Inserm, U545, F-59000, Lille, France
eUDSL, F-59000, Lille, France
f Institut Pasteur de Lille, F-59019, Lille, France
gDept. of Pathology and Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands
a r t i c l e i n f o a b s t r a c tArticle history:
Received 12 January 2010
Accepted 21 January 2010
Available online 29 January 2010
Edited by Veli-Pekka Lehto
Keywords:
Inﬂammation
Liver
Cholesterol
Mouse
Liver X receptor
Peroxisome proliferator-activated receptor0014-5793/$36.00  2010 Federation of European Bio
doi:10.1016/j.febslet.2010.01.046
Abbreviations: NASH, non-alcoholic steatohepat
APOE2ki, humanized apolipoprotein E2 knock-in; NA
disease; LDL, low density lipoprotein; HFC, high
fenoﬁbrate; PPARa, peroxisome proliferator-activ
T0901317; TG, triglyceride; Acox1, acyl-CoA oxidas
sterol regulatory element-binding protein ½; IPA,
Cept1, choline/ethanolaminephosphotransferase 1; F
binding cassette; Acaa, acetyl-CoA acyltransferase; Act
Acl, argininosuccinate lyase; Cyp7a1, cytochrome P4
P450 8b1; Fdft1, farnesyldiphosphatefarnesyltransfer
phate synthase; Gpdh, glyceraldehyde-3-phosphate d
CoA synthase; Insig2, insulin stimulated gene 2; L
spermidine/spermine n(1)-acyltransferase 1; Sc5dl, st
stearoyl-CoA desaturase
* Corresponding author.
E-mail address: kristiaan.wouters@insem.fr (K. WoHepatic inﬂammation is the key factor in non-alcoholic steatohepatitis (NASH) and promotes pro-
gression to liver damage. We recently identiﬁed dietary cholesterol as the cause of hepatic inﬂam-
mation in hyperlipidemic mice. We now show that hepatic transcriptome responses are strongly
dependent on cholesterol metabolism during diet-induced NASH and its inhibition by fenoﬁbrate.
Furthermore, we show that, despite doubling hepatic steatosis, pharmacological LXR activation
reverses hepatic inﬂammation, in parallel with reversing hepatic cholesterol levels. Together, the
results indicate a prominent role of cholesterol during the development, inhibition and reversal
of hepatic inﬂammation in NASH and reveal potential new therapeutic strategies against NASH.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is characterized by li-
pid accumulation in the liver (steatosis) and has become a major
health problem. NAFLD may progress towards a more harmful con-chemical Societies. Published by E
itis; LXR, liver X receptor;
FLD, non-alcoholic fatty liver
fat, high cholesterol; FF,
ated receptor alpha; T09,
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pl, lipoprotein lipase; SAT,
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uters).dition, i.e. non-alcoholic steatohepatitis (NASH), in which inﬂam-
mation is present. Ultimately, NASH can lead to further liver
damage such as ﬁbrosis, cirrhosis and liver failure [1,2].
We have previously shown that hyperlipidemic mice, like the
humanized apolipoprotein E2 knock-in (APOE2ki) mice and the
low density lipoprotein (LDL) receptor-deﬁcient mice, develop
NASH after only a few days of high fat, high cholesterol (HFC) feed-
ing [3,4]. In APOE2ki mice, the human APOE2 allele replaces the
murine variant and is expressed under the control of endogenous
promoter sequences in a tissue speciﬁc manner and at physiologi-
cal levels. APOE2 has a markedly reduced afﬁnity for the LDL recep-
tor, leading to a plasma lipoprotein proﬁle resembling human type
III hyperlipoproteinemia [5]. NASH development in APOE2ki mice
could be inhibited by co-administrating fenoﬁbrate (FF), a syn-
thetic ligand of peroxisome proliferator-activated receptor alpha
(PPARa) [3]. PPARa is a nuclear receptor with fatty acids as its nat-
ural ligands [6,7]. Upon activation, it initiates transcription of
genes involved in lipid metabolism resulting in increased fatty acid
oxidation [8].lsevier B.V. All rights reserved.
Fig. 1. Acox1 and Cte1 gene expression. Relative gene expression of Acox1 (A) and
Cte1 (B) in hepatic mRNA of APOE2ki female mice (black bar) and C57Bl/6 (B6)
female mice (white bar) on a chow diet.
Table 1
Activation of hepatic transcription factors. Table shows the regulation of genes according to IPA. Regulation determined by literature mining regulation is shown as " (up-
regulated by the transcription factor), or ; (down-regulated by the transcription factor). In numbers, the actual regulation of these genes in our dataset is shown by either diet
only (HFC) or the diet supplemented by fenoﬁbrate (HFCff); non-signiﬁcant regulation (P > 106) is shown by ‘‘ns”.
Gene Reported effect transcription factors Measured response
LXR PPARa SREBP HFC 2 days HFC 7 days HFCff 2 days HFCff 7 days
ABCA1 " ns 1.9 ns ns
ABCC3 " 1.7 1.5 2.7 2.3
ABCG5 " ns 1.5 1.7 ns
ACAA1 " 1.4 ns 3.1 4.1
ACAA2 " " 1.8 3.2 2.7 ns
acta1 " ns 9.3 ns 24
arg ; 1.5 1.6 ns 1.4
asl ; 1.8 2 ns ns
Cyp7a1 " ; ; ns 2.4 ns ns
CYP8B1 " " 1.9 2.5 ns ns
fdft1 " " ns 3.1 ns 1.9
fdps " ns 2.8 2.3 ns
gpdh " ns 1.8 ns ns
HMGCS " 1,5 ns ns 2,9
Insig2 1,5 ns 1,8 1,6
LpL " " " ns 2.8 2.2 3.3
SAT ; ns 2 ns ns
Sc5dl " " ns 1.4 ns ns
scd " " 1.2 ns ns 1.9
scd2 " " ns 2.6 ns ns
SREBP " ns 2.1 ns ns
ATP binding cassette (ABC), acetyl-coa acyltransferase (Acaa), actin alpha (Acta1), arginase (Arg), argininosuccinate lyase (Acl), cytochrome P450 7a1 (Cyp7a1), cytochrome
P450 8b1 (Cyp8b1), farnesyldiphosphatefarnesyltransferase 1 (Fdft1), farnesyldiphosphate synthase (Fdps), glyceraldehyde-3-phosphate dehydrogenase (Gpdh), HMGCoA
synthase (Hmgcs), insulin stimulated gene 2 (Insig2), lipoprotein lipase (Lpl), spermidine/spermine n(1)-acyltransferase 1 (SAT), sterol 55-desaturase-like (Sc5dl), stearoyl-
CoA desaturase (Scd), sterol regulatory element-binding protein ½ (SREBP).
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duced by feeding APOE2ki mice a HFC diet were investigated in de-
tail. We identiﬁed the cholesterol metabolism pathway to be of
major importance during the early development of NASH. Subse-
quently, we aimed to identify how cholesterol metabolism inﬂu-
ences NASH development and to investigate the role of
intrahepatic cholesterol and triglycerides during inhibition and
reversal of NASH by using pharmacological ligands of PPARa and
liver X receptor (LXR).
2. Materials and methods
2.1. Mice and diet
APOE2ki mice were housed under standard conditions. Experi-
ments were performed according to Dutch and French laws, ap-
proved by the Committee for Animal Welfare of Maastricht
University, Maastricht, The Netherlands, and the Pasteur Institute
review board, Lille, France. Groups of 10 homozygote female mice
were fed either chow or HFC [3] (diet 1635, SAFE, Villemoisson-
sur-orge, France) for 2 or 7 days with or without FF 0.2% (F6020,
Sigma–Aldrich, Zwijndrecht, the Netherlands). Additionally, mice
were given HFC for 2 months, followed by 5 days of gavage treat-
ment with an LXR agonist, T0901317 (T09), (30 mg/kg) or vehicle.
Mice were sacriﬁced by cervical dislocation. Tissues were isolated,
snap-frozen in liquid nitrogen and stored at 80 C.
2.2. RNA analysis
Hepatic mRNA extraction, cDNA synthesis, and microarray
data generation has been described previously [3]. In short,
microarray analysis was performed by selecting genes according
to their P-value of the diet/treatment effect for each delay coefﬁ-
cient (four P-values per probe set). For the multi-testing problem,
Bonferroni correction was used. Genes with a P-value lower than
106 were selected as signiﬁcantly regulated. Biological pathwayanalysis was done with ingenuity pathway analysis (IPA) (Ingenu-
ity Systems, Redwood City, USA) software. Microarray data were
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cation of gene-expression by quantitative PCR was done as de-
scribed previously [3], using cyclophillin A as reference gene.
Primers:
50-GCAGCCACCCCGAGGTAAA-30 (Cte1 forward), 50-GCCACGG
AGCCATTGATG-30 (Cte1 reverse), 50-TGTGACCCTTGGCTCTGTTCT-
30 (Acox1 forward), 50-GTAGTAAGATTCGTGGACCTCTG-30 (Acox1
reverse), 50-TTCCTCCTTTCACAGAATTATTCCA-30 (cyclophillin A for-
ward), 50-CCGCCAGTGCCATTATGG-30 (cyclophillin A reverse).
2.3. Lipid analysis
Hepatic cholesterol and triglyceride contents were measured as
described previously [3] or liver specimens were dried to constant
weight in a Speedvac (Savant); (oxy)sterols were extracted
overnight by chloroform/methanol (2:1) at 4 C. Cholesterol and
its precursors were determined after alkaline hydrolysis and
derivatization to the corresponding trimethylsilyl-ethers by gas
chromatography-ﬂame ionization detection and gas chromatogra-
phy-mass spectrometry as described before [9].
2.4. Histology
Frozen liver sections (7 lm) were ﬁxed in acetone and stained
with Mac1 (M1/70) antibodies. Pictures were taken with a Nikon
digital camera DMX1200 and ACT-1 v2.63 software (Nikon Corpo-
ration, Tokyo, Japan).
2.5. Statistical analysis
Groups were compared using two-tailed non-paired t-tests
using Graphpad Prism 4.0. Data are expressed as means ± S.E.M.
and considered signiﬁcant at P < 0.05.3. Results
As shown previously, HFC feeding results in an increase of both
plasma and liver triglyceride (TG) and cholesterol levels, both of
which were normalized by FF treatment [3]. Additionally, tran-
scriptome analysis has shown that PPARa-dependent transcrip-
tional responses in hyperlipidemic APOE2ki mice do not play a
prominent role in early HFC-induced changes in hepatic gene
expression [3]. Therefore, we compared basal expression levels of
two established PPARa target genes, i.e. acyl-CoA oxidase 1
(Acox1) and cytososlic acyl-coa thioesterase 1 (Cte1) in APOE2ki
livers with levels in C57BL6 wild type (WT) livers (Fig. 1). The dataFig. 2. Hepatic cholesterol and lathosterol levels. Measurement of cholesterol (A) and its
HFC diet (black bars) and HFC + FF (grey bars) feeding compared to livers of animals fedshowed no difference in expression, indicating that basal hepatic
PPARa activity in APOE2ki mice is equal compared to WT animals.
Interestingly, of the genes down-regulated by the diet and up-
regulated by FF (Supplementary Table 1), the group of genes in-
volved in cholesterol metabolism was over-represented (15% of
the regulated genes in this group). These genes included: Hmgcs1
and Fdft1, involved in cholesterol biosynthesis; AbcC3, involved in
hepatic bile acid transport [10]; and Insig2, a regulator of intracel-
lular cholesterol levels [11]. To acquire insight into the potential
impact of cholesterol metabolism-related transcription factors, a
literature search was performed on transcription factors involved
in cholesterol metabolism: LXR and sterol regulatory element-
binding protein ½ (SREBP). Changes in expression levels of target
genes present in our dataset were compared to their regulation
known in literature, as reported by IPA (Table 1). Genes known
to be induced by SREBP activation (acaa2, cyp8b1, fdft1, fps, hmgcs,
sc5dl) were rather inhibited upon HFC feeding, indicating an inhi-
bition of SREBP activity. In addition, LXR target genes (abca1,
abcg5, lpl, scd, scd2, srebp) were mostly regulated upon HFC in
the sense of LXR activation. The analysis thus suggests that these
cholesterol sensors (i.e. SREBP inhibition and LXR activation) are
major factors controlling regulation of lipid genes upon HFC
feeding.
We hypothesized that the observed regulation of LXR and
SREBP arises from increased hepatic cholesterol [11]. To assess this
hypothesis in vivo, intrahepatic levels of cholesterol and one of his
precursors, lathosterol, were measured in the liver. The levels of
both compounds were markedly increased upon HFC feeding
(Fig. 2).
Addition of FF to the HFC fed mice was shown previously to in-
hibit NASH development [3]. In parallel, FF treatment inhibited the
accumulation of hepatic cholesterol and its precursor lathosterol
(Fig. 2) as well as reversing the HFC-induced regulation of many
cholesterol metabolism-associated genes (Table 1, Supplementary
Table 1).
To distinctively elucidate the impact of intrahepatic cholesterol
on hepatic inﬂammation, we aimed to speciﬁcally decrease hepatic
cholesterol levels. Hereto, APOE2ki mice were given HFC for up to
2 months to establish NASH. Hereafter, animals were treated with
T09, a synthetic agonist of LXR. This agonist speciﬁcally lowers
cholesterol levels while increasing steatosis [12]. As expected,
treatment resulted in a tendency to decrease of plasma cholesterol
(1123 mg/dl ± 479 vs. 826 mg/dl ± 270), while inducing hypertri-
glyceridemia (200 mg/dl ± 139 vs. 1221 mg/dl ± 818). Furthermore,
T09 lowered intra-hepatic cholesterol dramatically (Fig. 3A) while
doubling steatosis (Fig. 3B). In accordance with hepatic cholesterol
levels, and despite doubling hepatic TG, inﬂammation was stronglyprecursor lathosterol (B) in the livers of female APOE2ki mice after 2 and 7 days of
a chow diet (white bars). * indicates signiﬁcant differences between groups.
Fig. 3. Reversal of NASH by T09. Measurement of hepatic cholesterol (A) and TG (B) and Mac1-positive cell count (C) in the livers of female APOE2ki mice after 2 months of
HFC (white bars) and after T09 treatment (black bars). Panel (D) shows representative pictures of Mac1 staining. * indicates signiﬁcant differences between groups.
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(inﬁltrating) Mac1-positive inﬂammatory cells. Parallel with its ef-
fects on hepatic cholesterol, LXR activation thus reversed inﬂam-
mation in a model of severe established NASH.
4. Discussion
Previously, we have shown that HFC feeding induces NASH very
rapidly in hyperlipidemic mice [3,4]. Current data show that the
lack of a PPARa signature in the hepatic transcriptional response
was not the consequence of an increased basal activity of this tran-
scription factor due to the increased basal lipid levels found in
APOE2ki mice. This supports the notion that other transcription
factors are likely to be more dominant. Although amongst the die-
tary components there were some putative PPARa ligands, it is
now becoming more clear that in vivo, PPARa activation relies
more on the generation of de novo ligands, such as 1-palmitoyl-
2-oleoyl-sn-glycerol-3-phosphocholine by fatty acid synthase and
choline/ethanolaminephosphotransferase 1 (Cept1) [13].
Current study also suggests that transcriptional responses in the
liver are mainly due to increased hepatic cholesterol levels, re-
ﬂected by the hepatic transcriptional response to HFC feeding. In
fact, we have previously found 30% of genes regulated by HFC to
be associated with cholesterol metabolism [3]. Current literature-
based search suggested that SREBP activity was generally inhib-
ited, as several genes regulated by this transcription factor were
down-regulated [14,15]. This is probably a consequence of nega-
tive feedback mechanisms resulting from the hepatic cholesterol
accumulation [16]. However, some SREBP target genes were up-
regulated, despite the presumed inhibition of SREBP by the ele-
vated cholesterol levels [15]. It is possible that for these genes,
the activation of LXR by oxysterols [14,17] overrides SREBP inhibi-
tion (Table 1).
Both LXR and SREBP have been reported as important players in
steatosis and NASH via the induction of lipogenesis [12,18]. In fact,
hepatic free cholesterol and SREBP levels have been shown to in-
crease in human NASH [19]. Moreover, a lipidomic analysis of hu-man livers has shown a progressive increase of free cholesterol
during different stages of NASH [20]. Additionally, mitochondrial
free cholesterol accumulation has been shown to sensitize the liver
for developing inﬂammation in rats through mitochondrial gluta-
thione depletion [21]. In addition, we have previously shown that
dietary cholesterol can provoke hepatic inﬂammation, possibly due
to direct Kupffer cell activation upon scavenging of remnant lipo-
proteins [4]. Together with our current results, these observations
underline the role of hepatic cholesterol as a probable cause of he-
patic inﬂammation.
In parallel with inhibitingNASHdevelopment inmice, FF supple-
mentation led to a decrease of intra-hepatic cholesterol levels. Fur-
thermore, a signiﬁcant fraction of the genes reversed by FF are
known to be involved in cholesterolmetabolism and contain known
or putative SREBP target genes [14], suggesting that the inhibition of
cholesterol accumulation in the liver contributed to the inhibition of
NASH. However, in mice, FF robustly inhibits hepatic TG
accumulation [3], which is thought to be the critical ﬁrst hit during
the development of NASH [22]. Consequently, to explore the exact
contribution of cholesterol metabolism on inﬂammation in the ab-
sence of TG accumulation, we reversed an established NASH with
T09, an LXR agonist. LXR is an oxysterol sensor which induces a set
of genes that modulate cholesterol uptake, transport, and efﬂux
[17,23,24]. Additionally, treatmentwith this compound induces ste-
atosis and hypertriglyceridemia by increased lipogenesis [12,16]
and free fatty acid (FFA) uptake via increased expression of the FFA
transporter CD36 [25] in mice. Increased lipogenesis has also been
shown inmice andmurine and human cell lines [12,16]. Our results
show that the accumulation of hepatic TG did not counteract the
ability of LXR activation to reduce inﬂammation and underline the
importance of the hepatic cholesterol/LXR pathway in NASH. How-
ever, it has to be kept in mind that LXR activation can modulate
inﬂammation directly [16], which also may have played a role.
Previously, we reported that male hyperlipidemic mice develop
hepatic inﬂammation even without any accumulation of hepatic
lipids and that, rather than hepatic triglyceride accumulation, die-
tary cholesterol consumption was causal for hepatic inﬂammation
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ther dissociate the development of steatosis and hepatic inﬂamma-
tion in these mouse models of NASH and, in addition to dietary
cholesterol, substantiate the importance of hepatic cholesterol
levels.
Some important clinical implications arise from our studies.
First, it has to be noted that in humans, the beneﬁcial effects, if
any, of FF treatment on steatohepatitis development are not com-
pletely understood. It has been shown that FF improves metabolic
syndrome parameters and liver tests, but effects on liver histology,
including steatosis scores, remained minimal [26]. However, it has
been suggested that FF may be of use in improving NASH with an
improved efﬁcacy when combined with statin treatment [27]. Sec-
ond, although the clinical use of LXR agonists is debated, they show
promise as potential targets against cardiovascular disease [16].
However, the clinical use of such agonists is severely doubted
due to their pro-steatotic properties, which has refrained them un-
til now to be used in human subjects. Steatosis itself is generally
considered a relatively benign and reversible condition, and detri-
mental outcome is often associated with the presence of inﬂamma-
tion [2,22]. In fact, one of the physiological roles of the liver is to
accumulate TG in response to prolonged fasting, which is necessary
for the energy homeostasis in the body and is mainly regulated by
this organ [28,29]. Additionally, TG may even be a protective pool
of FFA in the liver [30]. Moreover, LXR-induced steatosis does not
lead to worsening of hepatic insulin sensitivity in mice [31]. There-
fore, the arguments against LXR agonists as a potential treatment
against atherosclerosis in humans may have to be reconsidered.
Additionally, these results reinforce the central role of cholesterol
during the development of hepatic inﬂammation.
LXR agonists may thus well be considered as a potential treat-
ment for NASH, at least to treat its most harmful component, i.e.
inﬂammation; as lowering liver inﬂammation may be the ﬁrst con-
cern in the treatment of NASH, despite a possible increase in
steatosis.
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